Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality

Front Matter....Pages I-XIV
Front Matter....Pages 1-1
Receptor Subtypes and Endogenous Ligands: Rational Tools in the Search for Psychotropic Drugs....Pages 3-9
Histamine H 3 Receptors in the Brain: Potent and Selective Ligands....Pages 10-19
Targets for Neurotransmitter Receptor Research Using PET Scan: The Neuroleptic Binding Site....Pages 20-31
The Potential of Positron-Emission Tomography for Pharmacokinetic and Pharmacodynamic Studies of Neuroleptics....Pages 32-39
Neurotransmitter Interactions as a Target of Drug Action....Pages 40-51
E-10-Hydroxynortriptyline: Effects and Disposition of a Potential Novel Antidepressant....Pages 52-59
Molecular Graphics of Antidepressant Drugs and Metabolites....Pages 60-67
Negative Symptoms in Schizophrenia: A Target for New Drug Development....Pages 68-77
Front Matter....Pages 79-79
Clinical Effects of Selective Serotonin Reuptake Inhibitors....Pages 81-93
Effects of Serotonergic Agonists on Neuroendocrine Responses of Rhesus Monkeys and Patients with Depression and Anxiety Disorders....Pages 94-104
Theoretical and Practical Implications of a Controlled Trial of an α 2 -Adrenoceptor Antagonist in the Treatment of Depression....Pages 105-108
Selective Dopamine D 1 and D 2 Receptor Antagonists....Pages 109-122
Animal Pharmacology of Raclopride, a Selective Dopamine D 2 Antagonist....Pages 123-130
Benzodiazepine Receptor Subtypes and Their Possible Clinical Significance....Pages 131-137
Front Matter....Pages 139-139
Genetic Polymorphisms of Drug-Metabolizing Enzymes: Molecular Mechanisms....Pages 141-147
Genetic Polymorphism in Drug Oxidation....Pages 148-162
The Use of Human Liver Banks in Pharmacogenetic Research....Pages 163-171
Inhibitors of the Microsomal Oxidation of Psychotropic Drugs: Selectivity and Clinical Significance....Pages 172-180
Pharmacogenetics of Antidepressants....Pages 181-191
Pharmacokinetic and Clinical Significance of Genetic Variability in Psychotropic Drug Metabolism....Pages 192-200
Front Matter....Pages 139-139
Inhibition of Desipramine 2-Hydroxylation by Quinidine and Quinine in Rapid and Slow Debrisoquine Hydroxylators....Pages 201-205
Debrisoquine Oxidation Phenotype in Psychiatric Patients....Pages 206-210
Role of Pharmacogenetics in Drug Development....Pages 211-216
Front Matter....Pages 217-217
Clinical Implications of the Pharmacokinetics of Tricyclic Antidepressants....Pages 219-227
Detection of Populations at Risk Using Drug Monitoring Data....Pages 228-231
Hydroxy Metabolites of Tricyclic Antidepressants: Evaluation of Relative Cardiotoxicity....Pages 232-236
Therapeutic Drug Monitoring of Tricyclic Antidepressants: A Means of Avoiding Toxicity....Pages 237-243
Neuroleptic Drug Levels in Erythrocytes and in Plasma: Implications for Therapeutic Drug Monitoring....Pages 244-256
Active Metabolites of Neuroleptics in Plasma and CSF: Implications for Therapeutic Drug Monitoring....Pages 257-262
Hydroxyhaloperidol and Clinical Outcome in Schizophrenia....Pages 263-268
Plasma Level Monitoring for Maintenance Neuroleptic Therapy....Pages 269-279
Perphenazine Serum Levels in Patients on Standard Doses....Pages 280-283
Front Matter....Pages 285-285
From Animal Experiments to Clinical Dosing: Some Aspects of Preclinical Development of Antidepressants....Pages 287-295
Evaluation of Clinical and Biological Parameters in Healthy Volunteers: More than Pharmacokinetics and Side Effects?....Pages 296-302
Dose Finding and Serum Concentrations of Neuroleptics in the Treatment of Schizophrenic Patients....Pages 303-310
Post-Marketing Surveillance of Psychotropic Drugs....Pages 311-316
Back Matter....Pages 317-329